Brazil faces a growing challenge, cancer represents the second leading cause of death, with 625,000 new cases are expected yearly in the country in 2020–22, according to The World Cancer Research Fund. Breast, prostate, colorectal and lung cancers remain among the most common, highlighting the need for strengthened research capacity, earlier diagnosis and access to new therapeutic approaches.
The Letter of Intent sets out a framework for joint work across early-stage scientific discovery, the development of large-scale AI models for cancer research, and efforts to accelerate clinical trials for cancer vaccines and immune-based therapies. Together, these areas aim to support the development, evaluation, and delivery of next-generation cancer innovations for people across Brazil.
Professor Tim Elliott, Director of the Centre for Immuno-Oncology, said: “The Letter of Intent is the first step in cementing our shared mission to improve the lives and outlook for people with cancer, wherever they are in the world. It builds on lessons from our work in Mexico, where mirrored laboratory models have helped grow local capability and we hope to apply similar principles in Brazil to support sustainable research infrastructure, and accelerate innovation ultimately to improve human health.”
Speaking on behalf of the Brazilian delegation Fernanda de Negri, Secretary of Science, Technology, and Innovation in Health (SCTIE) Ministry of Health of Brazil said: “Brazil has a strong foundation in cancer research, and partnerships like this allow us to accelerate progress in critical areas such as mRNA technologies, AI and clinical studies. By building on the capacity already in place and learning from Oxford’s experience in global collaborations, we can strengthen our ability to develop and apply advanced cancer innovations within Brazil.”
Read the full story on the Nuffield Department of Medicine website.